--- title: "Pre-market hot trades in US stocks: Onto Innovation up 7.49% in pre-market; Intel up 5.24% in pre-market" type: "News" locale: "en" url: "https://longbridge.com/en/news/292632255.md" description: "Onto Innovation pre-market up 7.49%; Intel pre-market up 5.24%; NextCure pre-market up 313.30%; U-BX Tech pre-market up 62.38%; Shuttle Pharmaceuticals pre-market up 53.35%" datetime: "2026-07-14T13:12:36.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/292632255.md) - [en](https://longbridge.com/en/news/292632255.md) - [zh-HK](https://longbridge.com/zh-HK/news/292632255.md) --- # Pre-market hot trades in US stocks: Onto Innovation up 7.49% in pre-market; Intel up 5.24% in pre-market **Pre-market Hot Trades in US Stocks** Onto Innovation is up 7.49% in pre-market trading. Based on recent key news: 1. On July 14, MarketBeat pointed out that although Onto Innovation received a "Moderate Buy" rating from analysts, top analysts are more optimistic about five other stocks. This information may have affected investor confidence in Onto Innovation, leading to stock price fluctuations. 2. On July 13, MarketBeat's report emphasized that Onto Innovation was not included in the list of five stocks recommended by top analysts, which could negatively impact its market performance. 3. On July 11, a report from 24/7 Wall St. indicated that the chip industry is benefiting from a wave of AI manufacturing spending, but Onto Innovation has failed to dominate in this wave, which may affect its market performance. The chip industry is significantly driven by AI spending, leading to notable market volatility. Intel is up 5.24% in pre-market trading. Based on recent key news: 1. On July 13, Intel announced an investment of €5 billion to expand its factory in Ireland to increase data center processor output. This move reflects the company's increased confidence in future manufacturing business and AI-related demand, driving the stock price up. Source: Bloomberg 2. On July 13, Intel revealed at the JP Morgan Technology Conference that the ratio of CPUs to GPUs in AI systems has changed dramatically, with increased CPU demand in proxy AI scenarios, improving Xeon sales. Source: Zhitong Finance 3. On July 13, UBS raised Intel's target price from $83 to $121, reflecting optimistic market expectations for its future growth. Source: UBS Group. The semiconductor sector overall is weakening, and market risks need to be monitored. **Top Gainers in Pre-market US Stocks** NextCure is up 313.30% in pre-market trading. Based on recent key news: 1. On July 14, NextCure announced a merger with Avere Therapeutics, and will operate under the name Avere Therapeutics post-merger. This news significantly boosted NextCure's stock price, with a pre-market increase of 93%. 2. On July 14, NextCure announced it has secured $320 million in private financing to develop AVR-001, an experimental drug for inflammatory diseases. This financing plan has enhanced market confidence in the company's future development, driving the stock price up. 3. On July 14, NextCure's trading volume surged, exceeding 44 million shares traded, compared to an average daily trading volume of 37,000 shares over the past three months, indicating a strong market reaction to the merger news. The biotechnology sector has seen frequent merger activity recently, attracting high market attention U-BX Tech pre-market rose 62.38%, with no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Shuttle Pharmaceuticals pre-market rose 53.35%. Based on recent news, 1. On July 13, HRT Financial LP increased its direct holdings in Shuttle Pharmaceuticals to 61,271 shares. HRT Financial purchased 8,997 shares in the open market at prices ranging from $3.11 to $3.38 per share. This news indicates institutional investors' confidence in the company, driving the stock price significantly higher. 2. On July 13, HRT Financial reported a 10% stake in Shuttle Pharmaceuticals in Form 3 filings. The documents show that as of July 9, HRT Financial directly held 60,540 shares of common stock. This increase in holdings further bolstered market confidence in the company, leading to a significant rise in the stock price. The market reacted positively to the increase in institutional holdings ### Related Stocks - [ONTO.US](https://longbridge.com/en/quote/ONTO.US.md) - [INTC.US](https://longbridge.com/en/quote/INTC.US.md) - [NXTC.US](https://longbridge.com/en/quote/NXTC.US.md) - [UBXG.US](https://longbridge.com/en/quote/UBXG.US.md) - [SHPH.US](https://longbridge.com/en/quote/SHPH.US.md) ## Related News & Research - [Intel's (INTC) AI Growth Story Is Still in the Early Days](https://longbridge.com/en/news/294158147.md) - [Key facts: Intel 15‑yr revenue high; margins >40%/17%; 14A/18A risk](https://longbridge.com/en/news/293815661.md) - [How the 'Nostradamus of AI' failed to spot a market crash](https://longbridge.com/en/news/294580418.md) - [A simple answer to AI job loss: Tax capital, not labor](https://longbridge.com/en/news/294491736.md) - [Meet the Gen Z AI whiz at the center of a hedge fund meltdown](https://longbridge.com/en/news/294425537.md)